Novartis is considering a “pay-for-performance” pricing scheme if its CAR-T therapy gets approved, following trial results published earlier this week.
This year’s ASCO conference has plenty of data from the CAR-T therapy contenders - but little known Chinese biotech Nanjing Biotech looks to have trumped all the established firms.
